Skip to content Skip to sidebar Skip to footer
Cytonics Corporation
Cytonics Corporation
Cytonics Corporation
Close

Cytonics is a privately held biotechnology company specializing in the development of diagnostics and therapeutics for osteoarthritis (OA), a disease of the joints that renders the afflicted immobile and in constant pain. Our first product was a biomarker assay for the detection of cartilage degradation products in damaged joints and the spine. This discovery led to the development of our first-generation therapy – a medical devices (510K) that leverages a naturally occuring blood proteing called A2M (alpha-2-macroglobulin) to halt the progression of osteoarthritis and shift the joint into an anabolic, restorative state.

Over 10,000 patients have been successfully treated with our first generation therapy, the “Autologous Protease Inhibitor Concentrate” (APIC) device, to date, cementing Cytonics as a leader in regenerative medicine research and development. The clinical and commercial success of APIC is the basis for our ongoing clinical development, and serves as a critical de-risking element for our entire R&D platform.

Now, we are working on a novel biologic treatment for osteoarthritis that may be the first and only disease-modifying therapy for the disease. This drug, dubbed “CYT-108,” is a variant of the natural A2M utilized in the APIC therapy. CYT-108 has completed Phase 1 clinical trials and is ready for Phase 2 development in 2026-2027.

For the People, By the People

We have raised over $30M from private equity and retail investors, with over $25M coming from everyday “Main Street” investors via equity crowdfunding. Cytonics has pioneered this investor first approach by eliminating Venture Capital from the equation and remaining independent of Big Pharma. With over 7,500 shareholders at our backs, we have demonstrated how the democratization of investing can lead to the democratization of drug development. This paradigm completely upends the traditional biotech industry by allowing individuals to decide what drug development programs advance by voting with their dollar.

The National Institute of Health also supported our research and awarded the company a prestigious $1.8M SBIR grant.

You can learn more about becoming a shareholder here: invest.cytonics.com

Get in touch with our CEO, Joey Bose: joey.bose@cytonics.com

Marketing by Katapult Marketing
© 2026 Cytonics Corporation – All rights reserved

Get fresh updates
Subscribe

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 30 East 23rd Street, 2nd Floor, NY, NY 10010, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA’s BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Receive News

Download Exclusive Investor Presentation & Stay Updated

Name(Required)
Privacy(Required)